Biocon Limited
ICICI Prudential Life Insurance bought 12,50,000 shares of Biocon Limited for ₹50 crore at ₹400 apiece in a block deal.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
Joint venture between ICICI Bank and Prudential plc. Total AUM in excess of Rs 3.2 lakh crore deployed across linked, participating and non-participating funds. CIO Manish Kumar has run the equity book for over a decade, with style biased to quality large and mid-caps. Active across primary and secondary markets through ULIP and group fund mandates.